The U.S. Food and Drug Administration approved CTI BioPharma Corp.’s drug for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-FDA-declines-to-approve-Avenues-non-opioid-painkiller-again-shares-drop-Reuters-6-14-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-02-28 21:20:002022-03-01 09:26:46FDA approves CTI BioPharma’s bone marrow cancer drug